Association of Disease Activity with Serum and Tear IL-2 Levels in Behçet Disease

References

• Behçet H. Uber rezidivierende Aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr Hamburg. 1937;105:1152–63
   Google Scholar
• Akkurt ZM1, Bozkurt M, Uçmak D, et al. Serum cytokine levels in Behçet's disease. J Clin Lab Anal. 2014; Aug 17. [Epub ahead of print]
   Google Scholar
• Sakane T, Suzuki N, Nagafuchi H. Etiopathology of Behcet's disease: immunological aspects. Yonsei Med J. 1997;38:350–8
   PubMedGoogle Scholar
• Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol. 2001; 2:797–801
   PubMed Web of Science ®Google Scholar
• Comarmond C, Wechsler B, Bodaghi B, et al. Biotherapies in Behçet's disease. Autoimmun Rev. 2014;13:762–9
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Squatrito D, et al. Behçet's syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med. 2014;9:257–65
   PubMed Web of Science ®Google Scholar
• Frassanito MA, Dammacco R, Cafforio P, et al. Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum. 1999;42:1967–74
   PubMed Web of Science ®Google Scholar
• Sugi-Ikai N, Nakazawa M, Nakamura S, et al. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behcet's disease. Invest Ophthalmol Vis Sci. 1998;39:996–1004
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Cayirli C, Er H, Yilmaz E. The levels of plasma interleukin-2 and soluble interleukin-2R in Behcet's disease: a marker of disease activity. J Dermatol. 1998;25:513–6
   PubMedGoogle Scholar
• Akkurt ZM, Bozkurt M, Uçmak D, et al. Serum cytokine levels in Behçet's disease. J Clin Lab Anal. 2014 Aug 17. [Epub ahead of print]
   Google Scholar
• Pekiner FN, Aytugar E, Demirel GY, et al. Interleukin-2, interleukin-6 and T regulatory cells in peripheral blood of patients with Behçet's disease and recurrent aphthous ulcerations. J Oral Pathol Med. 2012;41:73–9
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Topkarci Z. Is there a relation between clinical disease activity and acute phase response in Behcet's disease? Int J Dermatol. 2014;53:250–4
   PubMed Web of Science ®Google Scholar
• Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea. 2009;28:1023–7
   PubMed Web of Science ®Google Scholar
• International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078–80
   PubMed Web of Science ®Google Scholar
• Bhakta BB, Brennan P, James TE, et al. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38:728–33
   PubMed Web of Science ®Google Scholar
• Ng V, Cho P, Mak S, Lee A. Variability of tear protein levels in normal young adults: between-day variation. Graefes Arch Clin Exp Ophthalmol. 2000;238:892–9
   PubMed Web of Science ®Google Scholar
• Schirmer O. Studien zur Physiologie und Patholgie der Tranenabsonderung und Tranenabfuhr. Arch Klin Exp Ophthalmol. 1903;56:197
   Google Scholar
• Jones LT. The lacrimal secretory system and its treatment. Am J Ophthalmol. 1966; 62:47–60
   PubMed Web of Science ®Google Scholar
• Berger SL, King VL. The fluctuation of tear production in the dog. J Am Anim Hosp Assoc. 1998;34:79–83
   PubMed Web of Science ®Google Scholar
• Xu KP, Yagi Y, Toda I, et al. Tear function index: a new measure of dry eye. Arch Ophthalmol. 1995;113:84–8
   PubMed Web of Science ®Google Scholar
• Jorizzo JL, Hudson RD, Schmalstieg FC, et al. Behcet's syndrome: immune regulation, circulating immune complexes, neutrophils migration, and colchicine therapy. J Am Acad Dermatol. 1984;10:205–14
   PubMed Web of Science ®Google Scholar
• Crins ND, Röver C, Goralczyk AD, et al. Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies. Pediatr Transplant. 2014 Oct 4. [Epub ahead of print]
   Google Scholar
• Schattner A. Lymphokines in autoimmunity—a critical review. Clin Immunol Immunopathol. 1994;70:177–89
   PubMedGoogle Scholar
• Lee JH, Ha J, Kim SH, et al. IL-2 pathway blocking in combination with anti CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice. J Korean Med Sci. 2006;21:1005–11
   PubMed Web of Science ®Google Scholar
• Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park). 2002;16:4–10
   PubMed Web of Science ®Google Scholar
• Pahwa S, Morales M. Interleukin-2 therapy in HIV infection. AIDS Patient Care STDS. 1998;12:187–97
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;15;192:5451–8
   Web of Science ®Google Scholar
• Koarada S, Haruta Y, Tada Y, et al. Increased entry of CD4+ T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behcet's disease. Rheumatology (Oxford). 2004;43:843–51
   PubMed Web of Science ®Google Scholar
• Akdeniz N, Esrefoglu M, Keles MS, et al. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singapore. 2004;33:596–9
   PubMed Web of Science ®Google Scholar
• Yücel A, Dilek K, Saba D, et al. Interleukin-2 gene polymorphism in Turkish patients with Behçet's disease and its association with ocular involvement. Int J Immunogenet. 2013;40:349–55
   PubMed Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm. 2007;15:63–70
   PubMed Web of Science ®Google Scholar
• Oehninger-Gatti C, Buzo R, Alcantara JC, et al. [The use of biological markers in the diagnosis and follow-up of patients with multiple sclerosis. Test of five fluids]. Rev Neurol. 2000;30:977–9
   PubMed Web of Science ®Google Scholar
• Mrugacz M, Kaczmarski M, Bakunowicz-Lazarczyk A, et al. IL-8 and IFN-gamma in tear fluid of patients with cystic fibrosis. J Interferon Cytokine Res. 2006;26:71–5
   PubMed Web of Science ®Google Scholar
• Gunaydin I, Ustundag C, Kaner G, et al. The prevalence of Sjogren's syndrome in Behcet's syndrome. J Rheumatol. 1994;21:1662–4
   PubMed Web of Science ®Google Scholar
• Ramirez-Peredo J, Cetina JA, Alarcon-Segovia D. Sjogren's syndrome in Behcet's disease. Lancet. 1973;2:732
   PubMed Web of Science ®Google Scholar
• Namba K, Ogawa T, Inaba G, et al. Two cases of Behçet's disease with Sjögren's syndrome. In: Godeau R,Wechsier B, eds. Behçet's Disease. New York: Elsevier Science; 1993: 299–302
   Google Scholar